PIK3CA and esophageal squamous cell carcinoma: In agreement with the conclusion reached by Cui YP’s group [85], Garcia-Carracedo D et al [69], who employed a genetically engineered mouse model of ESCC, revealed that the PIK3CA mutation at H1047R sensitized ESCC cells to cisplatin and BYL719, a specific inhibitor that potently inhibits the two most common PIK3CA somatic mutations at H1047R and E545K, strongly indicating that the PIK3CA mutation at H1047R enables OSCC cell lines to be sensitive to cisplatin.